Valproic acid increases SMN levels in spinal muscular atrophy patient cells
Charlotte J. Sumner(Johns Hopkins University), Kenneth H. Fischbeck(National Institute of Neurological Disorders and Stroke), Brenna J. Hill(National Institute of Allergy and Infectious Diseases), Xiaocun Chen(Vertex Pharmaceuticals (United States)), Kristie R. Schussler(The Ohio State University), J. Stephen Perhac(National Institute of Neurological Disorders and Stroke), Jennifer A. Markowitz(National Institute of Neurological Disorders and Stroke), J. Paul Taylor(St. Jude Children's Research Hospital), Daniel D. Coovert(University of Minnesota), Jill Jarecki(Vertex Pharmaceuticals (United States)), Thanh N. Huynh(National Institute of Neurological Disorders and Stroke), Arthur H.M. Burghes(The Ohio State University Wexner Medical Center)
Cited by 288
Related Papers
Tau protein liquid–liquid phase separation can initiate tau aggregation
|The EMBO Journal|2018|1.1k
The Duchenne muscular dystrophy gene product is localized in sarcolemma of human skeletal muscle
|Nature|1988|659
Myoblast Transfer in the Treatment of Duchenne's Muscular Dystrophy
|New England Journal of Medicine|1995|522
Myasthenia Gravis
|New England Journal of Medicine|1977|435
CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study: a cross-sectional analysis
|Journal of Neurology Neurosurgery & Psychiatry|2014|342